Compare TGLS & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | DMRA |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2011 | 2020 |
| Metric | TGLS | DMRA |
|---|---|---|
| Price | $37.67 | $18.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $55.75 | $46.89 |
| AVG Volume (30 Days) | 333.1K | ★ 669.9K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | N/A | ★ 121.48 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $370,984,000.00 | N/A |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $11.39 | N/A |
| P/E Ratio | $28.95 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $34.05 | $16.50 |
| 52 Week High | $63.46 | $34.89 |
| Indicator | TGLS | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 33.52 |
| Support Level | $37.43 | $18.73 |
| Resistance Level | $46.99 | $26.76 |
| Average True Range (ATR) | 1.34 | 1.35 |
| MACD | 0.43 | 0.08 |
| Stochastic Oscillator | 78.08 | 22.39 |
Tecnoglass Holdings Inc, formerly Tecnoglass Inc, is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.